16 June 2014: On 29 May 2014, the Board of Oxford BioMedica plc (LSE: OXB), (the “Company” or “Oxford BioMedica”), the leading gene based biopharmaceutical company, announced details of a proposed share issue to raise gross proceeds of up to £25.7 million (£23.7 million net of expenses) including a £20 million firm fundraising of 1,000,018,815 new ordinary shares at a price of 2 pence per share (the “New Ordinary Shares”) (the “Firm Fundraising”) and an open offer of up to 283,229,801 New Ordinary Shares (the “Open Offer)” at a price of 2 pence per New Ordinary Share. Defined terms used in this announcement shall have the same meaning as those terms defined and used in the prospectus of the Company dated 29 May 2014, unless otherwise stated.
The Company has received valid acceptances in respect of 78,417,099 Open Offer Shares from Qualifying Shareholders. This represents approximately 27.7 per cent. of the Open Offer Shares offered. All eligible applications received from Qualifying Shareholders will be allocated their pre-emption entitlements and all eligible applications under the Excess Application Facility will be allocated their Open Offer Shares as applied for. Consequently, the Company has conditionally raised £21.6 million (before expenses) from the Firm Fundraising and the Open Offer
The Firm Placing and Open Offer remain conditional, amongst other things, upon the passing of the Resolutions at the General Meeting, to be held today, 16 June 2014, at 10:00 a.m. and Admission occurring no later than 8.00 a.m. on 17 June 2014 or such later time or date as the parties to the Placing Agreement may determine.
Application has been made to the UK Listing Authority (“UKLA”) for the New Ordinary Shares to be admitted to the premium segment of the Official List and for the New Ordinary Shares to be admitted to trading on the London Stock Exchange’s main market for listed securities. It is expected that Admission will become effective on 17 June 2014 and that dealings in the New Ordinary Shares will commence at 8.00 a.m. on 17 June 2014. Thereafter, Oxford BioMedica will have a total of 2,494,584,919 Ordinary Shares in issue.
The New Ordinary Shares, when issued and fully paid will rank equally in all respects with the Existing Ordinary Shares.
This announcement should be read in conjunction with the full text of the Prospectus. A copy of the Prospectus is available at the UKLA’s National Storage Mechanism and will be available for inspection at www.hemscott.com/nsm . In addition, the Prospectus is available to view on the “Investors” section of the Company’s website at www.oxfordbiomedica.co.uk. Copies of the Prospectus are also available from the offices of Oxford BioMedica plc, Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford, OX4 4GA.
For further information please contact:
Oxford BioMedica plc
Tel: +44 (0)1865 783 000
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Media Enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Emma Thompson/Matthew Neal
Tel: +44 (0)20 3709 5700
Sponsor
Charles Stanley & Co. Limited
Phil Davies
Tel: +44 (0)20 7739 8200
Financial Adviser & Broker
WG Partners
David Wilson
Claes Spång
Tel: +44 (0)20 3693 1566
Help employers find you! Check out all the jobs and post your resume.
